Literature DB >> 30800635

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma.

Nooshin Zargari1, Maral Mokhtari1.   

Abstract

OBJECTIVE: The diagnosis of thyroid tumors is based on histologic features, but the distinction between benign and malignant thyroid lesions is somehow difficult, especially in lesions with a follicular pattern. Thus, ancillary studies, such as immunohistochemistry (IHC), may be helpful. In this study, we aimed to evaluate the diagnostic value of 2 IHC markers, TROP-2 and HBME-1, in the diagnosis of thyroid cancers. STUDY
DESIGN: A total of 102 cases of thyroid lesions, including papillary thyroid carcinoma (classic variant) (29 cases), follicular variant of papillary thyroid carcinoma (21 cases), multinodular goiter (22 cases), follicular adenoma (24 cases), and follicular carcinoma (6 cases) were selected. The hematoxylin-eosin slides were reviewed for confirmation of diagnosis, and IHC examination for TROP-2 and HBME-1 was performed. RESULT: HBME-1 had 84% sensitivity and 98% specificity with a positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 83%. TROP-2 had 93% sensitivity and 74% specificity with a PPV of 81% and an NPV of 90% in malignant thyroid lesions.
CONCLUSION: IHC panel consisting of TROP-2 and HBME-1 can be used in equivocal follicular patterned lesions for the diagnosis of thyroid carcinomas.

Entities:  

Keywords:  Follicular adenoma; Follicular carcinoma; HBME-1; Multinodular goiter; Papillary thyroid carcinoma; TROP-2; Thyroid

Year:  2018        PMID: 30800635      PMCID: PMC6381885          DOI: 10.1159/000494430

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  12 in total

1.  Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.

Authors:  Emine Aycan Mataraci; Banu Yilmaz Ozgüven; Fevziye Kabukçuoglu
Journal:  Pol J Pathol       Date:  2012-03       Impact factor: 1.072

Review 2.  Application of immunohistochemistry in thyroid pathology.

Authors:  Haiyan Liu; Fan Lin
Journal:  Arch Pathol Lab Med       Date:  2015-01       Impact factor: 5.534

3.  Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.

Authors:  Samar M Abd-El Raouf; Taiseer R Ibrahim
Journal:  Pathol Res Pract       Date:  2014-06-27       Impact factor: 3.250

4.  Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

Authors:  Husain A Saleh; Bo Jin; John Barnwell; Opada Alzohaili
Journal:  Diagn Pathol       Date:  2010-01-26       Impact factor: 2.644

5.  Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.

Authors:  Ivan Paunovic; Tijana Isic; Marija Havelka; Svetislav Tatic; Dubravka Cvejic; Svetlana Savin
Journal:  APMIS       Date:  2011-11-19       Impact factor: 3.205

6.  Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.

Authors:  S Palo; D S Biligi
Journal:  Malays J Pathol       Date:  2017-04       Impact factor: 0.656

7.  TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.

Authors:  Andrey Bychkov; Pichet Sampatanukul; Shanop Shuangshoti; Somboon Keelawat
Journal:  Pathology       Date:  2016-06-14       Impact factor: 5.306

8.  Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.

Authors:  Hongyu Guan; Zejun Guo; Weiwei Liang; Hai Li; Guohong Wei; Lijuan Xu; Haipeng Xiao; Yanbing Li
Journal:  BMC Cancer       Date:  2017-07-14       Impact factor: 4.430

9.  A study of Galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm.

Authors:  Alliya Muzafar; Mulazim Hussain Bukhari; Ihtesham Uddin Qureshi
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

10.  Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.

Authors:  Debdas Bose; Ram Narayan Das; Uttara Chatterjee; Uma Banerjee
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04
View more
  7 in total

1.  Survival-based bioinformatics analysis to identify hub long non-coding RNAs along with lncRNA-miRNA-mRNA network for potential diagnosis/prognosis of thyroid cancer.

Authors:  Pejman Morovat; Saman Morovat; Milad Hosseinpour; Forough Ghasem Zadeh Moslabeh; Mohammad Javad Kamali; Ali Akbar Samadani
Journal:  J Cell Commun Signal       Date:  2022-09-23       Impact factor: 5.908

2.  Digital gene expression analysis might aid in the diagnosis of thyroid cancer.

Authors:  H Armanious; B Adam; D Meunier; K Formenti; I Izevbaye
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

Review 3.  Diagnostic challenges in the gray-zone lesions of fine-needle aspiration cytology.

Authors:  Shruti Gupta; Pranab Dey
Journal:  Cytojournal       Date:  2021-09-10       Impact factor: 2.091

4.  Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.

Authors:  Dalia A Elsers; Mahmoud R A Hussein; Mohammed Hassan Osman; Ghada A Mohamed; Ghada Hosny
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

5.  Application Value of Color Doppler Ultrasonography Combined with Thyroid Autoantibody Tests in Early Diagnosis of Thyroid Cancer.

Authors:  Danlin Song; Fajin Dong; Jing Zheng; Hui Luo; Jinxi Wei
Journal:  Comput Math Methods Med       Date:  2022-04-27       Impact factor: 2.809

6.  Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation.

Authors:  Baoping Zhang; Shuting Gao; Ruiping Li; Yiting Li; Rui Cao; Jingyang Cheng; Yumeng Guo; Errui Wang; Ying Huang; Kailiang Zhang
Journal:  BMC Cancer       Date:  2020-08-27       Impact factor: 4.430

7.  Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules.

Authors:  Yan Xiong; Xin Li; Li Liang; Dong Li; Limin Yan; Xueying Li; Jiting Di; Ting Li
Journal:  Virchows Arch       Date:  2021-07-26       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.